ABSTRACT
OBJECTIVE: To measure the effectiveness and safety of imatinib for gstrointestinal stromal tumors (GISTs). METHOD: A retrospective study from 1993 through June 2005 by identifying all patients diagnosed with GIST by the Pathology Department. The medical records of those treated with imatinib were reviewed. Demographic, diagnostic, therapeutic, and outcome-related data were collected. RESULTS: Twenty-five patients were identified, 7 of them treated with imatinib. Total responses were 4/7; 2/7 cases were complete responses, and 2/7 were partial responses. Mean actuarial disease-free survival was 10 months, and overall survival was 44 months. Adverse reactions (ARs) reported included: 33% (5) gastrointestinal events, 40% (6) dermatologic events and/or edema, 14% (2) blood toxicity, and 13% (2) asthenia. In all, 2/7 patients experienced no imatinib-related toxicity. CONCLUSIONS: In our experience, imatinib is an effective, well tolerated therapy for malignant [c-Kit (CD117)-positive], non-resectable and/or metastatic GIST.
Subject(s)
Antineoplastic Agents/therapeutic use , Gastrointestinal Stromal Tumors/drug therapy , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Adult , Aged , Benzamides , Female , Humans , Imatinib Mesylate , Male , Middle Aged , Retrospective StudiesABSTRACT
Objetivo: Medir la efectividad y seguridad de imatinib en lostumores del estroma gastrointestinal (GIST).Método: Estudio retrospectivo desde el año 1993 hasta juniode 2005 donde se identificaron todos los pacientes diagnosticadosde GIST por anatomía patológica, y se revisaron historias clínicasde los tratados con imatinib. Se recogieron datos demográficos,relativos al diagnóstico, al tratamiento y a la evolución.Resultados: Se identificaron 25 pacientes, 7 tratados conimatinib. La respuesta total fue de 4/7, 2/7 casos fueron respuestascompletas y otros 2/7 respuestas parciales. La mediana actuarialde supervivencia libre de enfermedad alcanzada fue de 10meses y la global 44 meses. Las reacciones adversas (RAM) recogidasfueron: 33% (5) gastrointestinales, 40% (6) dermatológicasy/o edema, 14% (2) toxicidad hematológica y 13% (2) astenia. El2/7 pacientes no experimentaron ningún tipo de toxicidad relacionadacon imatinib.Conclusiones: En nuestra experiencia, imatinib constituye untratamiento efectivo y de buena tolerancia para el GIST maligno[c-Kit (CD117) positivo] no resecable y/o metastásico
Objective: To measure the effectiveness and safety of imatinibfor gstrointestinal stromal tumors (GISTs).Method: A retrospective study from 1993 through June 2005by identifying all patients diagnosed with GIST by the PathologyDepartment. The medical records of those treated with imatinibwere reviewed. Demographic, diagnostic, therapeutic, and outcome-related data were collected.Results: Twenty-five patients were identified, 7 of them treatedwith imatinib. Total responses were 4/7; 2/7 cases were completeresponses, and 2/7 were partial responses. Mean actuarialdisease-free survival was 10 months, and overall survival was 44months. Adverse reactions (ARs) reported included: 33% (5) gastrointestinalevents, 40% (6) dermatologic events and/or edema,14% (2) blood toxicity, and 13% (2) asthenia. In all, 2/7 patientsexperienced no imatinib-related toxicity.Conclusions: In our experience, imatinib is an effective, welltolerated therapy for malignant [c-Kit (CD117)-positive], nonresectableand/or metastatic GIST